These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Subscribe To Our Newsletter & Stay Updated
